Literature DB >> 29055144

Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade.

L Fania1, G Di Zenzo1, B Didona1, M A Pilla1, L Sobrino1, A Panebianco1, C Mazzanti1, D Abeni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29055144     DOI： 10.1111/jdv.14649

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

3.  Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Yuichiro Iwamoto; Takatoshi Anno; Katsumasa Koyama; Fumiko Kawasaki; Kohei Kaku; Koichi Tomoda; Seiko Sugiyama; Yumi Aoyama; Hideaki Kaneto
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

Review 4.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.